Prior virologic and biochemical studies have shown phenotypic antagonism between K65R and multiple thymidine-analogue mutations (TAMs) in site-directed mutants tested in vitro. We hypothesized, on the basis of this observed antagonism, that K65R and T215Y/F with multiple TAMs would not be selected on the same human immunodeficiency virus type 1 genome in vivo. We searched a large database of patient genotypes ( ) for the frequency of K65R in combination with у3 TAMs as determined by standard population n p 59,262 sequencing. K65R and multiple TAMs were rarely detected (!0.1%) in the same plasma sample. Samples with both K65R and у3 TAMs ( ) were further analyzed by use of single-genome sequencing. K65R was n p 21 never found on the same genome with T215F/Y and у2 other TAMs, except in the presence of the Q151M multiple nucleoside reverse-transcriptase inhibitor (NRTI)-resistance complex. These results indicate that antagonism between the K65R and T215Y/F pathways of NRTI resistance occurs at the genomic level. Therapy with NRTI combinations that select both pathways simultaneously may delay the emergence of NRTI resistance and prolong treatment response.
analogue through phosphorolysis, which results in primer unblocking and resumption of polymerization [1, 5] . Of the TAMs, T215F and T215Y are most important for high-level zidovudine resistance and the excision phenotype [6] [7] [8] .
The K65R mutation in HIV-1 RT causes decreased susceptibility to all NRTIs approved by the US Food and Drug Administration (FDA), except for zidovudine [9] . K65R reverses resistance to zidovudine mediated by TAMs [10] , and the antagonism between K65R and TAMs is bidirectional: TAMs also decrease K65R-mediated resistance to abacavir, tenofovir, and didanosine. We have shown that K65R reverses the phenotypic effects of TAMs by decreasing ATP-catalyzed phosphorolysis [11, 12] . Additionally, kinetic analyses of RT have shown that TAMs reduce the selectivity of K65R for incorporation of the natural substrate dATP over the incorporation of tenofovir diphosphate [13] .
Recent clinical observations have supported the hypothesis that K65R and TAMs are antagonistic and that there is counterselection of these mutations in vivo. In a genotypic analysis of 160,000 samples submitted for clinical testing, K65R was negatively associated with specific TAMs, including M41L, D67N, L210W, and T215F/Y [12] . Other researchers have also reported a negative association of K65R and TAMs, particularly with T215F/Y, in genotype databases [14, 15] .
This has led to the hypothesis that the use of thymidine analogues (primarily zidovudine) may prevent the emergence of K65R [16] . Recent data from clinical trials have supported this hypothesis. In studies of a triple-NRTI regimen that excluded zidovudine, 24%-92% patients whose therapy was failing had virus with the K65R mutation [17] [18] [19] [20] [21] [22] . By contrast, only 1 of 90 patients with treatment failure in trials of 3 or 4 NRTIs that included zidovudine had virus with the K65R mutation [23, 24] . The 1 patient with treatment failure who had virus with the K65R mutation had received only once-daily zidovudine. Other clinical and in vitro studies have reported that the selection of K65R and TAMs is generally mutually exclusive [25] [26] [27] [28] .
These observations suggest that the existence of K65R and TAMs on the same genome would not be favorable for HIV-1. Yet, in a small number of patients, K65R and TAMs have been detected in plasma samples by use of standard genotype analysis (also referred to as population or "bulk" sequencing). Whether these mutations exist on the same or different HIV-1 genomes can not be determined by standard genotype analysis, which provides a composite of the mutations present in the virus population. In the present study, therefore, we used a new single-genome sequencing (SGS) method [29] to determine whether K65R and TAMs, including T215F/Y, are linked on the same genome. SGS allows the analysis of mutational linkage through sequencing of polymerase chain reaction (PCR)-amplified cDNA derived from individual viral genomes [29] . To find appropriate specimens for testing, we searched a large database of standard genotypes to identify plasma samples that had both K65R and multiple TAMs according to the results of standard genotype analysis.
MATERIALS AND METHODS
Plasma samples. The samples analyzed consisted of 59,262 plasma specimens without patient identifiers submitted to Laboratory Corporation of America (LabCorp) for HIV-1 genotyping over the course of a 2-year period from January 2003 through December 2004. Samples were predominantly from community-based practices, although they did include a small number of clinical trial specimens (658 samples). None of the plasma samples analyzed using SGS were from clinical trials. Patient antiretroviral treatment histories were not available. HIV-1 RNA quantification and standard genotyping were performed by LabCorp. Samples were considered for SGS if standard genotyping identified K65R and у3 TAMs (including or excluding T215F/Y) or K65R with T215F/Y alone or with any number of other TAMs. Testing of samples by SGS was approved by the Institutional Review Board of the University of Pittsburgh.
Database queries. The LabCorp genotype database was initially searched for the number of specimens with (1) K65R or (2) у1 TAM. Group 2 (samples with у1 TAM) was further divided into subsets as follows: (2a) samples with 1 or 2 TAMs, (2b) samples with у3 TAMs, (2c) samples with T215F/Y only or with 1 other TAM, and (2d) samples with T215F/Y and у2 other TAMs. For these searches, TAMs were defined as any of the following mutations, unless otherwise specified: M41L, D67N, K70R, L210W, T215F, T215Y, and K219Q/E. In addition to the simple searches described above, combination queries were conducted to determine the number of samples that fitted у2 search criteria, combined with the Boolean operator "and." Two such searches were conducted. The first combination search queried the association of K65R with TAMs. Query criteria were as follows: (3) samples with K65R and (3a) no TAMs, (3b) 1 or 2 TAMs, or (3c) у3 TAMs. In addition, the same query was conducted to identify samples with (4) K65R, T215F/Y, and (4a) 0 or 1 other TAM or (4b) у2 other TAMs. The second combination search queried the presence of TAMs without K65R. Query criteria were as follows: (5) samples without K65R that had (5a) 1 or 2 TAMs or (5b) у3 TAMs. In addition, queries were conducted to specifically assess the frequency of T215F/Y with the following criteria: (6) samples with T215F/Y but not K65R and (6a) 0 or 1 other TAM or (6b) у2 other TAMs.
Standard genotype. HIV-1 RNA was pelleted by ultracentrifugation at 23,871 g from 0.5-1.0 mL of plasma. RNA was extracted from the pellet using the QIAamp viral RNA kit (Qiagen). The viral RNA equivalent of 50-100 mL of plasma was reverse transcribed and amplified with PCR using Expand High Fidelity Enzyme Mix (Roche Applied Science). A 1.7-kb fragment was then sequenced, including the entire protease gene and the 5 coding region of the RT region through codon 399. PCR products were sequenced in both directions using fluorescent dye-labeled sequencing terminators (ABI Prism BigDye Terminators; Applied Biosystems), followed by capillary electrophoresis on an ABI 3700 device (Applied Biosystems). Sequence assembly, alignment, and analysis were performed using Sequencher software (version 4.2; Genecodes) and comparison with the HIV-1 reference strain HXB2. Electropherograms were examined to confirm the sequence calls made by the software. Mutations associated with resistance (International AIDS Society-USA drug-resistance mutations) [30] were captured in the GenoSure database (LabCorp).
SGS. To obtain sequences derived from individual cDNAs, the SGS method was used as described elsewhere [29] . Briefly, HIV-1 RNA was extracted from plasma samples by centrifugation at 16,000 g; treatment of the virion pellet with proteinase K, guanidinium isothiocyanate, and glycogen; precipitation NOTE. NA, not applicable. a The expected no. was calculated using probability theory, in which the actual frequency of 2 subsets were multiplied to obtain the expected frequency. The expected frequency was multiplied by sample size to get the expected no. b Statistical significance was determined using x 2 analysis.
with 100% isopropanol; and washing with 70% ethanol. The purified RNA was resuspended in Tris-HCl and then was combined with deoxynucleotide triphosphates and random hexamers (Invitrogen). After denaturation, cDNA was synthesized by reverse transcribing viral RNA using the following components: MgCl 2 , RNase Out (Invitrogen), dithiothreitol, 1ϫ RT buffer (Invitrogen), and Superscript II RT (Invitrogen). cDNA was serially diluted and amplified by PCR using Platinum Taq DNA Polymerase High Fidelity (Invitrogen). According to Poisson distribution, if 30% of the PCR reactions are positive, it is expected that the amplification product arose from a single cDNA molecule in 4 of 5 instances. Positive PCR results were detected using an E-gel system (Invitrogen) and were sequenced using ABI Prism BigDye Terminator version 3.1 dideoxyterminator cycle sequencing (Applied Biosystems). Sequences were analyzed using Sequencher software (version 4.5; GeneCodes), and those that contained mixtures at any position were excluded from analysis. Resistance mutations from analyzed sequences were identified using the Stanford HIV Drug Resistance Database algorithm [31] . Control experiments demonstrated that the misincorporation rate for SGS was !0.01% and that assay-associated recombination between 2 closely related viral templates occurred at a frequency of !1 crossover/66,000 bp analyzed [29] . Statistical analysis. x 2 analysis was performed using GraphPad QuickCalcs software (version 2005; GraphPad).
RESULTS

Frequency of samples with K65R and TAMs by standard genotyping.
To determine whether K65R and TAMs are negatively associated, we first searched a large genotype database ( ), to examine the frequency of plasma samples havn p 59,262 ing both K65R and TAMs as determined by standard population sequencing. In our query, the following mutations were included as TAMs: M41L, D67N, K70R, L210W, T215F, T215Y, The expected number of samples with K65R and 1 or 2 TAMs was similar to the actual number in the database (280 expected vs. 305 actual). This difference was not statistically significant, which indicates the lack of significant interaction between K65R and 1 or 2 TAMs. By contrast, K65R was present in samples with у3 TAMs much less frequently than expected (52 actual vs. 322 expected;
). In addition, significantly fewer sam-P ! .001 ples than expected (73 actual vs. 416 expected;
) had P ! .001 both K65R and T215F/Y with any number of other TAMs (table  1) . Similar results were obtained when T215F and T215Y were separately analyzed for the frequency of occurrence with K65R and other TAMs (table 1) . This strong negative association between K65R and TAMs that include T215Y/F is consistent with previous virologic and biochemical studies that have demonstrated bidirectional phenotypic antagonism between these mutations [12, 13] . These observations led us to hypothesize that, although the K65R and T215F/Y mutations can be rarely detected in plasma samples by standard population genotyping, they will not be encoded on the same genome. To test this, we performed SGS on plasma samples from the 3 subsets that had significantly lower frequencies of K65R and TAMs than expected: (1) samples with K65R, T215F/Y, and у2 TAMs; (2) samples with K65R and T215F/Y with 0 or 1 other TAM; and (3) samples with K65R and у3 TAMs excluding T215F/Y (table 1) .
Single-genome sequences from plasma samples with K65R, T215F/Y, and у2 other TAMs. In the LabCorp database, 24 samples had K65R, T215F/Y, and у2 other TAMs (table 1); 10 of these samples were available for SGS. Antiretroviral treatment histories were not available. We sequenced 19-22 genomes from each plasma sample, except for 1 sample that had a low number of HIV-1 RNA copies (11 genomes sequenced) and 2 samples that were difficult to amplify (2 genomes sequenced from each). Table 2 shows HIV-1 RNA loads (in copies per milliliter) in the plasma samples, the NRTI mutations identified by standard genotyping, and the proportion of single genomes with the K65R mutation, TAMs, and other NRTI mutations.
None of the 158 genomes had both K65R and T215F/Y with у2 TAMs in the absence of the Q151M multiple-NRTI resistance complex. There were 2 instances in which K65R and T215F/Y were observed on the same genome: in the presence of Q151M and at least 2 other mutations in the Q151M multiple-NRTI resistance complex (22/158 genomes) or in the presence of T215F/Y with only 1 other TAM (5/158 genomes). All 5 of these genomes had K65R with M41L/T215Y on the same genome and were from the same patient plasma sample. K65R occurred with T215F/Y and у2 TAMs with Q151M in 3 sam- D67N, K70R , and 219E) in 3 of 30 genomes from 1 sample (C1). Although these genomes did not have Q151M, all 3 had V75I, which is associated with the Q151M complex. K65R occurred with 3 TAMs (67N, 70R, and 219Q) in 1 of 9 genomes . These data clearly demonstrate the mutual antagonism of K65R and TAMs at the genomic level. The sequences described in the present article have been submitted to GenBank (accession numbers DQ536888-DQ537207).
DISCUSSION
The high rates of recombination between HIV quasi species within an infected individual [33, 34] should result in linkage between K65R and TAMs, even in the absence of positive selection. On the basis of the actual number of specimens with K65R (1881 specimens) and with T215F/Y with у2 TAMs (8411 specimens) from our database of 59,262 specimens, 269 specimens would be expected to have both K65R and T215F/Y with у2 TAMs (table 1) . The actual number of plasma samples that had both K65R and T215F/Y with у2 TAMs, as determined by standard genotype analysis, was significantly lower than expected (24 specimens;
). Additionally, from the 320 total P ! .001 genomes tested from 21 patient plasma samples, K65R was not found on the same genome as T215F/Y with у2 TAMs, except when the Q151M multiple-NRTI resistance complex was present. Strong functional antagonism between these mutations is the most likely explanation for this mutual exclusivity between K65R and T215F/Y with у2 TAMs.
We have previously shown phenotypic antagonism between K65R and TAMs in viral and enzyme studies [12, 13] . Recombinant HIV-1 with K65R and 2 different combinations of TAMs (one containing T215F and the other containing T215Y) resulted in reversal of zidovudine resistance and reversal of or significant decreases in tenofovir and abacavir resistance conferred by K65R. Furthermore, kinetic analysis showed that K65R diminishes the excision activity of TAMs and that TAMs antagonize the selectivity of K65R for the incorporation of dNTP over NRTI-triphosphate. The present results corroborate these in vitro findings by showing that linkage between K65R and T215Y/F with multiple TAMs on the same genome rarely occurs in vivo. We found only 2 circumstances in which K65R and T215F/ Y with other TAMs were found on the same genome: when Q151M and several of its associated mutations of the multiple-NRTI resistance complex were also present and when T215F/ Y was present with 0 or 1 other TAM. To illustrate, of the 45 single genomes that had both K65R and T215F/Y, 22 also had Q151M and/or at least 2 other mutations from the Q151M multiple-NRTI resistance complex (A62V, V75I, V77L, and/or F116Y). Q151M confers low-level multiple-NRTI resistance, whereas the other mutations in the complex contribute to the phenotype and help retain replication capacity [35] [36] [37] . The primary mutation in this complex, Q151M, decreases the rate of incorporation of NRTIs but has been found to have minimal, if any, excision activity [38] . Its coexistence on the same genome with K65R and multiple TAMs suggests that the Q151M complex is a viral escape mechanism required for NRTI resistance in the context of the bidirectionally antagonistic K65R and TAM pathways (figure 1). However, additional studies of clones with K65R, TAMs, and the Q151M complex are needed to elucidate the role of the Q151M complex in facilitating the coexistence of K65R and T215F/Y on the same genome. The drug selection leading to this complex set of mutations on a single genome could not be determined by our study because patient treatment histories were unavailable.
Of the 23 single genomes with 65R and T215F/Y in the absence of the Q151M multiple-NRTI complex, all had T215F/ Y alone or with only 1 other TAM. Six genomes from 1 patient had K65R and T215F, 12 genomes from another patient had K65R and T215Y, and 5 genomes from a third patient had K65R, M41L, and T215Y. It is unknown why at least 3 TAMs, including T215Y/F, are necessary for the exclusion of K65R from the same genome. One explanation may be that the antagonism of K65R by TAMs is not significant with !3 TAMs or without T215F/Y. Meyer et al. [6] showed that the ATPdependent removal of zidovudine-monophosphate is least efficient with T215Y alone and that increases in excision efficiency correlate with the presence of additional TAMs. Alternatively, fewer TAMs could suggest that there was no continued selection for the efficient excision of zidovudine (i.e., zidovudine therapy had been stopped). The more common occurrence of K65R on the same genome with the TAM revertants T215D/I [39, 40] is consistent with this. It would have been useful to determine how mutational patterns evolved in patients with K65R, TAMs, and other changes at TAM codons, but sequential samples were not available for the present study.
Two other studies have reported the coexistence of K65R and T215Y on the same genome. Using clonal analysis, Wirden et al. [41] sequenced 27 clones from 1 plasma sample that had both K65R and T215Y by population sequencing. Only 1 clone was found to have K65R and T215F with 2 other TAMs (M41L and L210W). This patient was not receiving a regimen that included zidovudine, and other genomes from the same patient (4/27) had the T215Y revertant T215D. A second study by Colson et al. [42, 43] found K65R and T215Y on the same genome by clonal analysis in 2 of 3201 patients, but the coexistence of other TAMs was not reported. To our knowledge, our study is the first comprehensive analysis of a large database of patient samples that uses both statistical analyses and a novel sequencing method (SGS) that minimizes assay-related recombination events [29] . The studies by Wirden To conclude, we propose a model of 2 major pathways of NRTI resistance and their interactions (figure 1). HIV-1 evolves to acquire resistance to didanosine, zalcitabine, stavudine, lamivudine, abacavir, tenofovir, and emtricitabine via a pathway of discrimination that is primarily mediated by K65R, L74V, or M184V. Of these 3 mutations, K65R is of particular concern because it can reduce HIV-1 susceptibility to almost all investigational and FDA-approved NRTIs except those with a 3 -azido group [9] . HIV-1 evolves to acquire resistance to zidovudine or stavudine and cross-resistance to other NRTIs via a pathway of excision mediated by TAMs, with T215F/Y being a key mutation. The K65R and T215Y/F TAM pathways are bidirectionally antagonistic and are counterselected in patients. The present results demonstrate that this antagonism occurs at the genomic level in vivo. Simultaneous therapy with NRTIs that select for mutations with antagonistic mechanisms of resistance may prolong treatment response and prevent the emergence of K65R.
